1. Назаренко Т.А. «Агонизировать» или «антагонизировать» циклы стимуляции гонадотропинами? Стимуляция функции яичников. М., 2008; с. 96–8..
2. Albano C, Grimbizis G, Smitz J et al. The luteal phase of non-supplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin-releasing hormone antagonist Cetrorelix. Fertil Steril 1998; 70: 357–9.
3. Al-Inany H, Aboulghar M. GnRH antagonist in assisted reproduction: a Cochrane review. Hum Reprod 2002; 17 (4): 874–85.
4. Daya S. Cost-effective, evidence-based infertility care. Curr Opin Obstet Gynecol 2000 Jun; 12(3):227-31.
5. de Klerk C, Macklon NS, Heijnen EM et al. The psychological impact of IVF failure after two or more cycles of IVF with a mild versus standard treatment strategy. Hum Reprod 2007; 22 (9): 2554–8.
6. Devroey P., et al. Improving the patient’s experience of IVF/ICSI: a proposal for an ovarian stimulation protocol with GnRH antagonist co-treatment. Hum Reprod 2009; 24(4):764-74.
7. Edwards RG, Lobo R, Bouchard P. Time to revolutionize ovarian stimulation. Hum Reprod 1996; 11: 917–9.
8. Engel JB, Griesinger G, Schultze-Mosgau A et al. GnRH agonists and antagonists in assisted reproduction: pregnancy rate. Reprod Biomed Online 2006; 13 (1): 84.
9. European and Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRHantagonist ganirelix or a long protocol of the GnRHagonist triptorelin for the prevention of premature LHsurges in women undergoing ovarian stimulation. Hum Reprod 2001; 16 (4): 644–51.
10. The European Orgalutran Study Group, Borm G, and Mannaerts B. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. Hum Reprod 2000; 15: 1490–8.
11. Fauser BC, Jong D, Olivenness F et al. Endocrine profiles after triggering of final oocyte maturation with GnRH agonists after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vivo fertilization. J Clin Endocrinol Metab 2002; 2: 2144–50.
12. Fluker M, Grifo J, Leader A et al. North American Ganirelix Study Group. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril 2001; 75 (1): 38–45.
13. Griesinger G, Diedrich K, Tarlatzis BC, Kolibianakis EM. GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysis. Reprod Biomed Online 2006; 13 (5): 628–38.
14. Griesinger G, Felberbaum R, Diedrich K. GnRHantagonists in ovarian stimulation: a treatment regimen of clinicians’ second choice? Data from the German national IVF registry. Hum Reprod 2005; 20 (9): 2373–5.
15. Heijnen EM, Eijkemans MJ, De Klerk C et al. A mild treatment strategy for in-vitro fertilisation: a randomized non-inferiority trial. Lancet 2007; 369 (9563): 743–9.
16. Hohmann FP, Macklon NS, Fauser BCJM. A Randomized Comparison of Two Ovarian Stimulation Protocols with Gonadotropin-Releasing Hormone (GnRH) Antagonist Cotreatment for in Vitro Fertilization Commencing Recombinant Follicle-Stimulating Hormone on Cycle Day 2 or 5 with the Standard Long GnRH Agonist Protocol. J Clin Endocrinol Metab 2003; 88: 166–73.
17. Hughes EG, Fedorkow DM, Daya S et al. The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials. Fertil Steril 1992; 58 (5): 888–96.
18. Huirne JA, Homburg R, Lambalk CB. Are GnRH antagonists comparable to agonists for use in IVF? Hum Reprod 2007; 22 (11): 2805–13.
19. Huirne JA, van Loenen AC, Schats R et al. Dose-finding study of daily gonadotropin-releasing hormone (GnRH) antagonist for the prevention of premature luteinizing hormone surges in IVF/ICSI patients: antide and hormone levels. Hum Reprod 2004; 19 (10): 2206–15.
20. Itskovitz-Eldor J, Kol S, Mannaerts B. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report. Hum Reprod 2000; 15: 1965–8.
21. Janssens RM, Brus L, Cahill DJ et al. Direct ovarian effects and safety aspects of GnRH agonists and antagonists. Hum Reprod Update 2000; 6 (5): 505–18.
22. Jurema MW, Bracero NJ, Garcia JE. Fine tuning cycle day 3 hormonal assessment of ovarian reserve improves in vitro fertilization outcome in gonadotropin-releasing hormone antagonist cycles. Fertil Steril 2003; 80 (5): 1156–61.
23. Keay SD, Liversedge NH, Mathur RS, Jenkins JM. Assisted conception following poor ovarian response to gonadotrophin stimulation. Br J Obstet Gynaecol 1997; 104 (5): 521–7.
24. Klipstein S, Reindollar RH, Regan MM, Alper MM. Initiation of the gonadotropin-releasing hormone antagonist ganirelix for in vitro fertilization cycles in which the lead follicle is >14 mm. Fertil Steril 2004; 81 (3): 714–5.
25. Kolibianakis EM, Albano C, Camus M et al. Initiation of gonadotropin-releasing hormone antagonist on day 1 as compared to day 6 of stimulation: effect on hormonal levels and follicular development in in vitro fertilization cycles. J Clin Endocrinol Metab 2003; 88 (12): 5632–7.
26. Out HJ, Mannaerts BM. The gonadotrophin-releasing hormone antagonist ganirelix--history and introductory data. Hum Fertil (Camb) 2002; 5 (1): G5–10.
27. Propst AM, Bates GW, Robinson RD et al. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer. Fertil Steril 2006; 86: 58.
28. Qublan HS, Amarin Z, Tahat YA et al. Kilani Ovarian cyst formation following GnRH agonist administration in IVF cycles: incidence and impact. Hum Reprod March 2006; 21: 640–4.
29. Rackow BW, Kliman HJ, Taylor HS. GnRH antagonists may affect endometrial receptivity. Fertility and Sterility 2008; 89 (5): 1234–9.
30. Ragni G, Vegetti W, Riccaboni A et al. Comparison of GnRHagonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome. Hum Reprod 2005; 20 (9): 2421–5.
31. Shoham Z, Balen Al, Patel A, Jabobs HS. Results of ovulation induction using human menopausal gonadotropin or purified follicle-stumulation hormone in hypogonadotropic hyplgonadism patients. Fertil Steril 1991; 56: 1048–53.
32. Simon C, Oberyé J, Bellver J et al. Similar endometrial development in oocyte donors treated with either high- or standard-dose GnRH antagonist compared to treatment with a GnRH agonist or in natural cycles. Hum Reprod December 2005; 20: 3318–27.
33. Sunkara SK, Tuthill J, Khairy M et al. Pituitary suppression regimens in poor responders undergoing IVF treatment: a systematic review and meta-analysis. Reprod Biomed Online 2007; 15 (5): 539–46.
34. Templeton A, Morris JK. Reducing the risk of multiple births by transfer of two embryos after in vitro fertilization. N Engl J Med 1998; 339: 573–7.
35. Trew GH. Optimizing gonadotrophin-releasing hormone antagonist protocols. Hum Fertil 2002; 5 (1): G13-6; discussion G16-8, G41-8.
36. Alviggi C, Moll A, Clarizia R, De Placido G. Exploiting LH in ovarian stimulation. Reprod Biomed Online 2006; 12: 221–33.
________________________________________________
1. Назаренко Т.А. «Агонизировать» или «антагонизировать» циклы стимуляции гонадотропинами? Стимуляция функции яичников. М., 2008; с. 96–8..
2. Albano C, Grimbizis G, Smitz J et al. The luteal phase of non-supplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin-releasing hormone antagonist Cetrorelix. Fertil Steril 1998; 70: 357–9.
3. Al-Inany H, Aboulghar M. GnRH antagonist in assisted reproduction: a Cochrane review. Hum Reprod 2002; 17 (4): 874–85.
4. Daya S. Cost-effective, evidence-based infertility care. Curr Opin Obstet Gynecol 2000 Jun; 12(3):227-31.
5. de Klerk C, Macklon NS, Heijnen EM et al. The psychological impact of IVF failure after two or more cycles of IVF with a mild versus standard treatment strategy. Hum Reprod 2007; 22 (9): 2554–8.
6. Devroey P., et al. Improving the patient’s experience of IVF/ICSI: a proposal for an ovarian stimulation protocol with GnRH antagonist co-treatment. Hum Reprod 2009; 24(4):764-74.
7. Edwards RG, Lobo R, Bouchard P. Time to revolutionize ovarian stimulation. Hum Reprod 1996; 11: 917–9.
8. Engel JB, Griesinger G, Schultze-Mosgau A et al. GnRH agonists and antagonists in assisted reproduction: pregnancy rate. Reprod Biomed Online 2006; 13 (1): 84.
9. European and Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRHantagonist ganirelix or a long protocol of the GnRHagonist triptorelin for the prevention of premature LHsurges in women undergoing ovarian stimulation. Hum Reprod 2001; 16 (4): 644–51.
10. The European Orgalutran Study Group, Borm G, and Mannaerts B. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. Hum Reprod 2000; 15: 1490–8.
11. Fauser BC, Jong D, Olivenness F et al. Endocrine profiles after triggering of final oocyte maturation with GnRH agonists after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vivo fertilization. J Clin Endocrinol Metab 2002; 2: 2144–50.
12. Fluker M, Grifo J, Leader A et al. North American Ganirelix Study Group. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril 2001; 75 (1): 38–45.
13. Griesinger G, Diedrich K, Tarlatzis BC, Kolibianakis EM. GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysis. Reprod Biomed Online 2006; 13 (5): 628–38.
14. Griesinger G, Felberbaum R, Diedrich K. GnRHantagonists in ovarian stimulation: a treatment regimen of clinicians’ second choice? Data from the German national IVF registry. Hum Reprod 2005; 20 (9): 2373–5.
15. Heijnen EM, Eijkemans MJ, De Klerk C et al. A mild treatment strategy for in-vitro fertilisation: a randomized non-inferiority trial. Lancet 2007; 369 (9563): 743–9.
16. Hohmann FP, Macklon NS, Fauser BCJM. A Randomized Comparison of Two Ovarian Stimulation Protocols with Gonadotropin-Releasing Hormone (GnRH) Antagonist Cotreatment for in Vitro Fertilization Commencing Recombinant Follicle-Stimulating Hormone on Cycle Day 2 or 5 with the Standard Long GnRH Agonist Protocol. J Clin Endocrinol Metab 2003; 88: 166–73.
17. Hughes EG, Fedorkow DM, Daya S et al. The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials. Fertil Steril 1992; 58 (5): 888–96.
18. Huirne JA, Homburg R, Lambalk CB. Are GnRH antagonists comparable to agonists for use in IVF? Hum Reprod 2007; 22 (11): 2805–13.
19. Huirne JA, van Loenen AC, Schats R et al. Dose-finding study of daily gonadotropin-releasing hormone (GnRH) antagonist for the prevention of premature luteinizing hormone surges in IVF/ICSI patients: antide and hormone levels. Hum Reprod 2004; 19 (10): 2206–15.
20. Itskovitz-Eldor J, Kol S, Mannaerts B. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report. Hum Reprod 2000; 15: 1965–8.
21. Janssens RM, Brus L, Cahill DJ et al. Direct ovarian effects and safety aspects of GnRH agonists and antagonists. Hum Reprod Update 2000; 6 (5): 505–18.
22. Jurema MW, Bracero NJ, Garcia JE. Fine tuning cycle day 3 hormonal assessment of ovarian reserve improves in vitro fertilization outcome in gonadotropin-releasing hormone antagonist cycles. Fertil Steril 2003; 80 (5): 1156–61.
23. Keay SD, Liversedge NH, Mathur RS, Jenkins JM. Assisted conception following poor ovarian response to gonadotrophin stimulation. Br J Obstet Gynaecol 1997; 104 (5): 521–7.
24. Klipstein S, Reindollar RH, Regan MM, Alper MM. Initiation of the gonadotropin-releasing hormone antagonist ganirelix for in vitro fertilization cycles in which the lead follicle is >14 mm. Fertil Steril 2004; 81 (3): 714–5.
25. Kolibianakis EM, Albano C, Camus M et al. Initiation of gonadotropin-releasing hormone antagonist on day 1 as compared to day 6 of stimulation: effect on hormonal levels and follicular development in in vitro fertilization cycles. J Clin Endocrinol Metab 2003; 88 (12): 5632–7.
26. Out HJ, Mannaerts BM. The gonadotrophin-releasing hormone antagonist ganirelix--history and introductory data. Hum Fertil (Camb) 2002; 5 (1): G5–10.
27. Propst AM, Bates GW, Robinson RD et al. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer. Fertil Steril 2006; 86: 58.
28. Qublan HS, Amarin Z, Tahat YA et al. Kilani Ovarian cyst formation following GnRH agonist administration in IVF cycles: incidence and impact. Hum Reprod March 2006; 21: 640–4.
29. Rackow BW, Kliman HJ, Taylor HS. GnRH antagonists may affect endometrial receptivity. Fertility and Sterility 2008; 89 (5): 1234–9.
30. Ragni G, Vegetti W, Riccaboni A et al. Comparison of GnRHagonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome. Hum Reprod 2005; 20 (9): 2421–5.
31. Shoham Z, Balen Al, Patel A, Jabobs HS. Results of ovulation induction using human menopausal gonadotropin or purified follicle-stumulation hormone in hypogonadotropic hyplgonadism patients. Fertil Steril 1991; 56: 1048–53.
32. Simon C, Oberyé J, Bellver J et al. Similar endometrial development in oocyte donors treated with either high- or standard-dose GnRH antagonist compared to treatment with a GnRH agonist or in natural cycles. Hum Reprod December 2005; 20: 3318–27.
33. Sunkara SK, Tuthill J, Khairy M et al. Pituitary suppression regimens in poor responders undergoing IVF treatment: a systematic review and meta-analysis. Reprod Biomed Online 2007; 15 (5): 539–46.
34. Templeton A, Morris JK. Reducing the risk of multiple births by transfer of two embryos after in vitro fertilization. N Engl J Med 1998; 339: 573–7.
35. Trew GH. Optimizing gonadotrophin-releasing hormone antagonist protocols. Hum Fertil 2002; 5 (1): G13-6; discussion G16-8, G41-8.
36. Alviggi C, Moll A, Clarizia R, De Placido G. Exploiting LH in ovarian stimulation. Reprod Biomed Online 2006; 12: 221–33.
Авторы
Т.В.Казначеева1, Е.Ю.Мартышкина2
1. Кафедра репродуктивной медицины и хирургии (зав. – акад. проф. РАМН Л.В.Адамян) ФПДО Московского медико-стоматологического университета;
2. Кафедра акушерства и гинекологии Государственной классической академии им. Маймонида (ректор – акад. В.Р.Ирина-Коган), Москва